Doxazosin Tablet
Product Images NDC 60505-0095

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 60505-0095). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doxazosin-1mg-100.jpg (Doxazosin 1mg 100)

Label for Doxazosin Tablets, USP 1 mg oral tablets by Apotex Corp. The label indicates a package of 100 tablets. It includes storage instructions, a barcode, and states the product is for prescription use only (Rx only). The label also provides manufacturer information and a link for patient information.*

FDA Label Image

Doxazosin-2mg-100.jpg (Doxazosin 2mg 100)

Doxazosin Tablets USP 2 mg tablet bottle label from Apotex Corp. The label states the product contains doxazosin mesylate equivalent to 2 mg doxazosin per tablet and includes storage instructions and dispensing guidance. The package size is 100 tablets, with the NDC 60505-0094-0, manufactured by Apotex Inc., Ontario, Canada.*

FDA Label Image

Doxazosin-4mg-100.jpg (Doxazosin 4mg 100)

Doxazosin Tablets, USP 4 mg oral tablets in a package of 100 tablets by Apotex Corp. The label includes storage instructions and mentions each tablet contains doxazosin mesylate equivalent to 4 mg doxazosin. It displays the NDC 60505-0095-0 and barcode, with directions for pharmacists to dispense with patient information.*

FDA Label Image

Doxazosin-8mg-100.jpg (Doxazosin 8mg 100)

Doxazosin Tablets, USP 8 mg, oral tablet by Apotex Corp. The label shows 100 tablets per container. It includes storage instructions to keep at 20-25°C with permitted excursions to 15-30°C, notes to dispense in a light-resistant container, and directs the pharmacist to provide patient information. The NDC is 60505-0096-0.*

FDA Label Image

Doxazosin-structure.jpg (Doxazosin Structure)

Chemical structure of doxazosin, showing its molecular arrangement including methoxy groups, a quinazoline core, a piperazine ring, and an oxocyclohexyl moiety with a methanesulfonic acid component.*

FDA Label Image

Figure1.jpg (Figure1)

Two line graphs showing clinical data for Doxazosin treatment over 14 weeks. The first graph depicts the mean change in total symptom score from baseline, showing a greater decrease with Doxazosin compared to placebo. The second graph illustrates the mean increase in maximum urinary flow rate (mL/sec) from baseline, with Doxazosin achieving higher flow rates than placebo. Both graphs include statistical significance markers and sample sizes (N=50 for Doxazosin, N=47 for placebo).*

FDA Label Image

Table3.jpg (Table3)

A data table summarizing effectiveness data from placebo-controlled trials of Doxazosin, showing symptom scores and maximum flow rate changes at various doses (placebo, 4 mg, 8 mg). The table includes mean baseline values and mean changes, with significance indicators comparing Doxazosin to placebo. A bar chart visualizes maximum flow rate and symptom score changes for placebo, 4 mg, and 8 mg doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.